Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
ConclusionGLP-1 RA and SGLT-2i can be considered as first line monotherapies for select patients with high cardiovascular risks, renal disease, or weight loss requirements. However, pharmacoeconomic considerations along with lesser long-term safety outcomes should limit these agents ’ use in certain patients as the management of diabetes continues to transition towards shared-decision making.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Heart | History of Medicine | Metformin | Sodium | Study | Weight Loss